Concepts (267)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cholecystitis, Acute | 5 | 2019 | 30 | 1.680 |
Why?
|
| Medicaid | 3 | 2020 | 372 | 1.380 |
Why?
|
| Ursidae | 2 | 2020 | 12 | 1.170 |
Why?
|
| Laparoscopy | 3 | 2021 | 490 | 0.990 |
Why?
|
| Appendectomy | 3 | 2021 | 57 | 0.860 |
Why?
|
| Appendicitis | 4 | 2021 | 84 | 0.840 |
Why?
|
| General Surgery | 4 | 2024 | 211 | 0.800 |
Why?
|
| Hibernation | 2 | 2020 | 10 | 0.790 |
Why?
|
| Cholecystectomy, Laparoscopic | 3 | 2014 | 49 | 0.780 |
Why?
|
| Orbital Fractures | 2 | 2020 | 8 | 0.760 |
Why?
|
| Cholecystostomy | 4 | 2016 | 22 | 0.760 |
Why?
|
| Upper Extremity Deep Vein Thrombosis | 1 | 2022 | 5 | 0.730 |
Why?
|
| Occupational Injuries | 1 | 2022 | 37 | 0.730 |
Why?
|
| Central Venous Catheters | 1 | 2022 | 17 | 0.720 |
Why?
|
| Hematoma, Subdural | 1 | 2021 | 10 | 0.710 |
Why?
|
| Length of Stay | 7 | 2024 | 827 | 0.690 |
Why?
|
| Critical Care | 3 | 2016 | 402 | 0.680 |
Why?
|
| Insurance Coverage | 1 | 2021 | 98 | 0.670 |
Why?
|
| Intestine, Small | 2 | 2018 | 82 | 0.660 |
Why?
|
| Venous Thromboembolism | 3 | 2020 | 150 | 0.650 |
Why?
|
| Hemostasis | 1 | 2020 | 19 | 0.650 |
Why?
|
| Clinical Clerkship | 2 | 2011 | 94 | 0.640 |
Why?
|
| Fracture Fixation | 1 | 2020 | 18 | 0.630 |
Why?
|
| Pulmonary Embolism | 2 | 2022 | 196 | 0.620 |
Why?
|
| Surgical Procedures, Operative | 1 | 2021 | 141 | 0.620 |
Why?
|
| Trauma Centers | 1 | 2020 | 130 | 0.590 |
Why?
|
| Emergency Medical Services | 1 | 2022 | 261 | 0.580 |
Why?
|
| Retrospective Studies | 16 | 2024 | 6862 | 0.560 |
Why?
|
| Curriculum | 3 | 2011 | 608 | 0.560 |
Why?
|
| Intestinal Obstruction | 2 | 2018 | 51 | 0.550 |
Why?
|
| Intestinal Diseases | 1 | 2018 | 37 | 0.530 |
Why?
|
| Blood Coagulation | 1 | 2017 | 41 | 0.510 |
Why?
|
| Abdominal Pain | 1 | 2018 | 102 | 0.510 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2018 | 88 | 0.510 |
Why?
|
| Adult | 17 | 2024 | 17356 | 0.440 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 407 | 0.420 |
Why?
|
| Male | 26 | 2024 | 31042 | 0.410 |
Why?
|
| MicroRNAs | 1 | 2020 | 710 | 0.400 |
Why?
|
| Humans | 37 | 2024 | 65124 | 0.400 |
Why?
|
| Teaching | 2 | 2011 | 165 | 0.390 |
Why?
|
| Intraabdominal Infections | 1 | 2013 | 2 | 0.390 |
Why?
|
| Female | 24 | 2024 | 34016 | 0.370 |
Why?
|
| United States | 9 | 2022 | 8097 | 0.350 |
Why?
|
| Students, Medical | 2 | 2011 | 263 | 0.340 |
Why?
|
| Culture | 1 | 2011 | 82 | 0.330 |
Why?
|
| Career Choice | 1 | 2011 | 126 | 0.310 |
Why?
|
| Postoperative Complications | 5 | 2016 | 1322 | 0.300 |
Why?
|
| Intensive Care Units | 1 | 2013 | 420 | 0.300 |
Why?
|
| Middle Aged | 14 | 2024 | 18267 | 0.300 |
Why?
|
| Multiple Trauma | 2 | 2007 | 29 | 0.300 |
Why?
|
| Aortic Diseases | 2 | 2000 | 65 | 0.300 |
Why?
|
| Communication | 2 | 2010 | 597 | 0.290 |
Why?
|
| Gallbladder Diseases | 1 | 2008 | 26 | 0.290 |
Why?
|
| Seasons | 2 | 2020 | 139 | 0.280 |
Why?
|
| Time-to-Treatment | 2 | 2020 | 134 | 0.280 |
Why?
|
| Embolism, Air | 1 | 2007 | 10 | 0.270 |
Why?
|
| Physician-Patient Relations | 2 | 2010 | 427 | 0.270 |
Why?
|
| Tertiary Care Centers | 2 | 2018 | 111 | 0.260 |
Why?
|
| Massachusetts | 3 | 2020 | 2145 | 0.260 |
Why?
|
| Omeprazole | 1 | 2006 | 5 | 0.250 |
Why?
|
| Gallbladder | 1 | 2006 | 40 | 0.240 |
Why?
|
| Proton Pump Inhibitors | 1 | 2006 | 47 | 0.240 |
Why?
|
| Aged | 13 | 2019 | 14958 | 0.210 |
Why?
|
| Gravity Suits | 2 | 2002 | 2 | 0.210 |
Why?
|
| Fibrinolysis | 2 | 2002 | 5 | 0.210 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 367 | 0.210 |
Why?
|
| Emergency Service, Hospital | 2 | 2022 | 1149 | 0.200 |
Why?
|
| Farmers | 1 | 2022 | 20 | 0.190 |
Why?
|
| Academic Medical Centers | 3 | 2021 | 306 | 0.180 |
Why?
|
| Reaction Time | 1 | 2022 | 130 | 0.180 |
Why?
|
| Upper Extremity | 1 | 2022 | 54 | 0.180 |
Why?
|
| Glasgow Coma Scale | 1 | 2021 | 48 | 0.170 |
Why?
|
| Internship and Residency | 2 | 2024 | 805 | 0.170 |
Why?
|
| Injury Severity Score | 1 | 2021 | 117 | 0.170 |
Why?
|
| Risk Factors | 4 | 2022 | 5429 | 0.170 |
Why?
|
| Thrombophlebitis | 1 | 2000 | 14 | 0.160 |
Why?
|
| Antithrombin III | 1 | 2020 | 15 | 0.160 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2000 | 32 | 0.160 |
Why?
|
| Alcoholic Intoxication | 1 | 2020 | 27 | 0.160 |
Why?
|
| Libraries, Medical | 2 | 1990 | 5 | 0.150 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2011 | 161 | 0.150 |
Why?
|
| Up-Regulation | 1 | 2020 | 374 | 0.150 |
Why?
|
| Hepatocytes | 1 | 2020 | 222 | 0.140 |
Why?
|
| Intermittent Claudication | 1 | 1999 | 53 | 0.140 |
Why?
|
| Obesity | 2 | 2022 | 1273 | 0.140 |
Why?
|
| Carotid Stenosis | 1 | 1999 | 100 | 0.140 |
Why?
|
| Gastrointestinal Diseases | 2 | 2010 | 71 | 0.130 |
Why?
|
| Capsule Endoscopy | 1 | 2018 | 40 | 0.130 |
Why?
|
| Clinical Competence | 3 | 2011 | 727 | 0.130 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2018 | 74 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 2 | 2014 | 801 | 0.130 |
Why?
|
| Gene Silencing | 1 | 2020 | 430 | 0.130 |
Why?
|
| Walking | 1 | 1999 | 245 | 0.130 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 801 | 0.120 |
Why?
|
| Comorbidity | 1 | 2020 | 1119 | 0.120 |
Why?
|
| Paclitaxel | 2 | 1994 | 102 | 0.120 |
Why?
|
| Equipment Failure | 1 | 2016 | 63 | 0.120 |
Why?
|
| Anemia | 1 | 2018 | 132 | 0.120 |
Why?
|
| Recurrence | 1 | 2018 | 657 | 0.120 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 1566 | 0.120 |
Why?
|
| Patient Discharge | 1 | 2019 | 519 | 0.120 |
Why?
|
| Critical Illness | 2 | 2016 | 329 | 0.110 |
Why?
|
| Hospital Mortality | 1 | 2020 | 875 | 0.110 |
Why?
|
| Medicare | 1 | 2019 | 624 | 0.110 |
Why?
|
| Analysis of Variance | 2 | 2010 | 602 | 0.110 |
Why?
|
| Vena Cava Filters | 2 | 2009 | 23 | 0.110 |
Why?
|
| Cholecystectomy | 1 | 2014 | 34 | 0.110 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 5612 | 0.110 |
Why?
|
| Smoking | 1 | 1999 | 861 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2018 | 440 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2014 | 5788 | 0.100 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2013 | 4 | 0.100 |
Why?
|
| Appendiceal Neoplasms | 1 | 2013 | 9 | 0.100 |
Why?
|
| Patient Safety | 1 | 2016 | 259 | 0.100 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2013 | 31 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 1656 | 0.100 |
Why?
|
| Young Adult | 3 | 2019 | 4810 | 0.090 |
Why?
|
| Animals | 6 | 2020 | 21324 | 0.090 |
Why?
|
| MEDLARS | 2 | 1990 | 3 | 0.090 |
Why?
|
| Educational Measurement | 2 | 2010 | 213 | 0.090 |
Why?
|
| Deglutition Disorders | 1 | 1992 | 43 | 0.090 |
Why?
|
| Cross Infection | 1 | 2013 | 164 | 0.090 |
Why?
|
| Decompression, Surgical | 1 | 2011 | 70 | 0.080 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2011 | 90 | 0.080 |
Why?
|
| Interdisciplinary Communication | 1 | 2011 | 106 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 2703 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 1994 | 318 | 0.080 |
Why?
|
| Intubation | 1 | 2010 | 10 | 0.080 |
Why?
|
| Confidence Intervals | 1 | 2010 | 236 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2010 | 1015 | 0.080 |
Why?
|
| Computer User Training | 1 | 1990 | 7 | 0.080 |
Why?
|
| Empathy | 1 | 2010 | 69 | 0.080 |
Why?
|
| Professional-Patient Relations | 1 | 2010 | 126 | 0.080 |
Why?
|
| Patient Simulation | 1 | 2010 | 67 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 272 | 0.080 |
Why?
|
| Interprofessional Relations | 1 | 2010 | 137 | 0.080 |
Why?
|
| Thrombophilia | 1 | 2009 | 14 | 0.080 |
Why?
|
| Ultrasonography, Doppler, Duplex | 2 | 1999 | 47 | 0.070 |
Why?
|
| Decision Making | 1 | 2013 | 418 | 0.070 |
Why?
|
| Arterial Occlusive Diseases | 2 | 1999 | 67 | 0.070 |
Why?
|
| Algorithms | 1 | 2014 | 1048 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2010 | 754 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2014 | 3310 | 0.070 |
Why?
|
| Bariatric Surgery | 1 | 2009 | 65 | 0.070 |
Why?
|
| Databases, Factual | 1 | 1992 | 882 | 0.070 |
Why?
|
| Gastric Bypass | 1 | 2009 | 69 | 0.070 |
Why?
|
| Emotions | 1 | 2010 | 233 | 0.070 |
Why?
|
| Stents | 1 | 2011 | 498 | 0.070 |
Why?
|
| Radiography | 2 | 2007 | 555 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2007 | 122 | 0.070 |
Why?
|
| Judaism | 1 | 1986 | 1 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2011 | 2763 | 0.060 |
Why?
|
| Reference Values | 1 | 2006 | 327 | 0.060 |
Why?
|
| Ethics, Medical | 1 | 1986 | 40 | 0.060 |
Why?
|
| Movement | 1 | 2006 | 163 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2010 | 627 | 0.060 |
Why?
|
| Maryland | 1 | 2024 | 36 | 0.060 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 2 | 2002 | 15 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2002 | 126 | 0.050 |
Why?
|
| Glioma | 2 | 1994 | 101 | 0.050 |
Why?
|
| Pressure | 1 | 2002 | 78 | 0.050 |
Why?
|
| Age Factors | 2 | 2013 | 1585 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 348 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2002 | 112 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2024 | 2483 | 0.040 |
Why?
|
| Prevalence | 2 | 2009 | 1445 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2010 | 1698 | 0.040 |
Why?
|
| Peripheral Vascular Diseases | 1 | 1999 | 45 | 0.040 |
Why?
|
| Carotid Artery, Internal | 1 | 1999 | 69 | 0.040 |
Why?
|
| Exercise Tolerance | 1 | 1999 | 85 | 0.040 |
Why?
|
| Body Composition | 1 | 1999 | 155 | 0.040 |
Why?
|
| Aortic Aneurysm | 1 | 1999 | 81 | 0.040 |
Why?
|
| Forecasting | 1 | 1999 | 230 | 0.030 |
Why?
|
| Perception | 1 | 1999 | 181 | 0.030 |
Why?
|
| Hemodynamics | 1 | 1999 | 251 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 1999 | 123 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 1999 | 930 | 0.030 |
Why?
|
| Diplopia | 1 | 1996 | 8 | 0.030 |
Why?
|
| Blood Pressure | 1 | 1999 | 526 | 0.030 |
Why?
|
| Motor Activity | 1 | 1999 | 345 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 1999 | 1163 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 1996 | 84 | 0.030 |
Why?
|
| Rats | 3 | 1994 | 1994 | 0.030 |
Why?
|
| Accidents, Traffic | 1 | 1996 | 140 | 0.030 |
Why?
|
| Accidental Falls | 1 | 1996 | 128 | 0.030 |
Why?
|
| beta-Galactosidase | 1 | 1994 | 84 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1994 | 17 | 0.030 |
Why?
|
| Medulloblastoma | 1 | 1994 | 13 | 0.030 |
Why?
|
| Cerebellar Neoplasms | 1 | 1994 | 11 | 0.030 |
Why?
|
| Central Nervous System Neoplasms | 1 | 1994 | 39 | 0.030 |
Why?
|
| Carcinoid Tumor | 1 | 2013 | 12 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2010 | 2619 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 1994 | 426 | 0.020 |
Why?
|
| Grateful Med | 1 | 1992 | 1 | 0.020 |
Why?
|
| Cholecystography | 1 | 2011 | 14 | 0.020 |
Why?
|
| MEDLINE | 1 | 1992 | 13 | 0.020 |
Why?
|
| Cell Movement | 1 | 1994 | 480 | 0.020 |
Why?
|
| Catheterization | 1 | 2011 | 111 | 0.020 |
Why?
|
| Peptic Ulcer | 1 | 2010 | 18 | 0.020 |
Why?
|
| Education, Nursing, Graduate | 1 | 2011 | 56 | 0.020 |
Why?
|
| Cholecystitis | 1 | 2010 | 29 | 0.020 |
Why?
|
| Abdomen, Acute | 1 | 2010 | 23 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2011 | 204 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 1994 | 524 | 0.020 |
Why?
|
| Baltimore | 1 | 1990 | 14 | 0.020 |
Why?
|
| Diverticulitis | 1 | 2010 | 33 | 0.020 |
Why?
|
| Consultants | 1 | 1990 | 12 | 0.020 |
Why?
|
| Herniorrhaphy | 1 | 2010 | 71 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 1418 | 0.020 |
Why?
|
| National Library of Medicine (U.S.) | 1 | 1989 | 3 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 493 | 0.020 |
Why?
|
| Brain | 2 | 1994 | 1604 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1989 | 105 | 0.020 |
Why?
|
| Acute Disease | 1 | 2010 | 663 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2009 | 199 | 0.020 |
Why?
|
| Patient Selection | 1 | 2010 | 483 | 0.020 |
Why?
|
| Fees, Medical | 1 | 1986 | 1 | 0.010 |
Why?
|
| Autopsy | 1 | 1986 | 56 | 0.010 |
Why?
|
| Surgery, Plastic | 1 | 1986 | 19 | 0.010 |
Why?
|
| Abortion, Induced | 1 | 1986 | 29 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2009 | 897 | 0.010 |
Why?
|
| Software | 1 | 1989 | 400 | 0.010 |
Why?
|
| Patient Care | 1 | 1986 | 79 | 0.010 |
Why?
|
| Cesarean Section | 1 | 1986 | 100 | 0.010 |
Why?
|
| Pharmaceutical Preparations | 1 | 1986 | 120 | 0.010 |
Why?
|
| Quality of Life | 1 | 2011 | 1259 | 0.010 |
Why?
|
| Leg | 1 | 2002 | 87 | 0.010 |
Why?
|
| Adolescent | 1 | 2013 | 6305 | 0.010 |
Why?
|
| Abdomen | 1 | 2002 | 94 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 2102 | 0.010 |
Why?
|
| Heparin | 1 | 2002 | 118 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1986 | 1421 | 0.010 |
Why?
|
| Immobilization | 1 | 1999 | 14 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 1999 | 24 | 0.010 |
Why?
|
| Renal Artery | 1 | 1999 | 36 | 0.010 |
Why?
|
| Vena Cava, Inferior | 1 | 1999 | 33 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1999 | 175 | 0.010 |
Why?
|
| Vascular Patency | 1 | 1999 | 134 | 0.010 |
Why?
|
| Catheterization, Peripheral | 1 | 1999 | 50 | 0.010 |
Why?
|
| Titanium | 1 | 1999 | 59 | 0.010 |
Why?
|
| Patient Transfer | 1 | 1999 | 93 | 0.010 |
Why?
|
| Cause of Death | 1 | 1999 | 221 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1999 | 162 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2002 | 525 | 0.010 |
Why?
|
| Equipment Design | 1 | 1999 | 363 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 1999 | 298 | 0.010 |
Why?
|
| Rats, Inbred Lew | 1 | 1994 | 106 | 0.010 |
Why?
|
| Cell Transplantation | 1 | 1994 | 41 | 0.010 |
Why?
|
| Decanoic Acids | 1 | 1994 | 4 | 0.010 |
Why?
|
| Drug Implants | 1 | 1994 | 15 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 1994 | 58 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 1994 | 27 | 0.010 |
Why?
|
| Microcirculation | 1 | 1994 | 59 | 0.010 |
Why?
|
| Fluorescence | 1 | 1994 | 93 | 0.010 |
Why?
|
| Polyesters | 1 | 1994 | 45 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1994 | 111 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 1994 | 257 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1994 | 293 | 0.010 |
Why?
|
| Biopolymers | 1 | 1994 | 72 | 0.010 |
Why?
|
| Central Nervous System Diseases | 1 | 1994 | 57 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 1994 | 178 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 1994 | 401 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1994 | 576 | 0.010 |
Why?
|
| Neoplasms | 1 | 2002 | 1367 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1994 | 869 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1994 | 739 | 0.010 |
Why?
|
| Mice | 1 | 1994 | 11105 | 0.000 |
Why?
|